Inotrem Receives Approval to Expand Nangibotide Clinical Trial in Critically Ill COVID-19 Patients and Receives Additional Public Funding of €45 Million
12.7.2021 10:00:00 EEST | Business Wire | Press release
Inotrem S.A., a biotechnology company specializing in the development of immunotherapies targeting the TREM-1 pathway, announces that it has obtained authorization to pursue the clinical development of nangibotide up to registration in COVID-19 patients from both the French and Belgian competent authorities.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210712005071/en/
As part of this program, Inotrem receives additional 45 million euros in public funding under the "Capacity Building" Call for Expression of Interest, operated on behalf of the French government by Bpifrance, the French national investment bank, as part of the Programme d’investissements d’avenir (PIA) and the France Recovery Plan, bringing French state support for the project to a total of 52,5 million euros. This public funding will support Inotrem’s clinical program including the phase 2/3 study “ESSENTIAL” which aims to demonstrate the efficacy and safety of nangibotide in treating patients in respiratory distress with severe forms of COVID-19.
The primary endpoint is evaluation of the impact of nangibotide on the progression of disease in patients receiving ventilatory support due to COVID-19 as well as on the severity of the respiratory failure, duration of mechanical ventilation, length of stay in intensive care and mortality. In “ESSENTIAL”, a Phase 2/3 clinical program, up to 730 patients will be enrolled initially in France and Belgium and, possibly in other European countries. Pre-defined interim analyses will be conducted by an independent Data Monitoring Board to test futility and to allow for the study design to be adapted as necessary. “ESSNTIAL” is the continuation of a 60 patients phase 2a evaluating the safety and efficacy of nangibotide in patients suffering from severe COVID-19. In July 2020, the CoviTREM-1 consortium, which includes the Nancy and Limoges university hospitals and Inotrem, obtained public funding of 7,5 million euros under the “PSPC-COVID” call for projects, operated on behalf of the French government by Bpifrance
New pre-clinical studies with nangibotide have demonstrated that the administration of nangibotide in murine models infected with SARS-CoV-2 was associated with a decrease in inflammatory mediators and an improvement of clinical signs, in particular respiratory function, and survival. Inotrem also confirmed in 3 different and independent cohorts that sTREM-1, a marker of the activation of the TREM-1 biological pathway, is associated with both severity and mortality in critically ill COVID-19 patients.
Leveraging the results of these preclinical studies and the implications for the role of the TREM-1 pathway in COVID-19, Inotrem has filed additional patents to cover nangibotide use in severe forms of COVID-19 as well as the use of sTREM-1 as a biomarker and companion diagnostic. This significantly strengthens Inotrem’s already broad patent estate.
Jean-Jacques Garaud, Executive Vice-President, Head of Scientific and Medical Affairs and Inotrem’s co-founder said :“We are eager to pursue the development of nangibotide in these severe forms of COVID-19. Nangibotide is a TREM-1 inhibitor which has already demonstrated a trend towards efficacy in septic shock patients and has the potential to modulate the dysregulated immune response in critically ill COVID-19 patients. With this large clinical study, we can demonstrate efficacy for nangibotide in a further indication with the goals of reducing the duration of hospitalization and mortality.”
Sven Zimmerman, CEO of Inotrem, also declared: “The size of the financial support awarded to us as part of the French government’s initiative against COVID-19 is a testimony to the relevance of targeting the TREM-1 pathway with nangibotide in these severely ill patients. We are delighted by the confidence placed in our technology and our team. Everyone at Inotrem is fully committed to deliver on this ambitious program alongside nangibotide’s ongoing Phase 2b trial in septic shock patients.”
About Inotrem
Inotrem S.A. is a biotechnology company specialized in immunotherapy for acute and chronic inflammatory syndromes. The company has developed a new concept of immunomodulation that targets the TREM-1 pathway to control unbalanced inflammatory responses. Through its proprietary technology platform, Inotrem has developed the first-in-class TREM-1 inhibitor, LR12 (nangibotide), with potential applications in a number of therapeutic indications such as septic shock and myocardial infarction. In parallel, Inotrem has also launched another program to develop a new therapeutic modality targeting chronic inflammatory diseases. The company was founded in 2013 by Dr. Jean-Jacques Garaud, a former head of research and early development at the Roche Group, Prof. Sébastien Gibot and Dr. Marc Derive. Inotrem is supported by leading European and North American investors.
About TREM-1 pathway
TREM-1 pathway is an amplification loop of the immune response that triggers an exuberant and hyperactivated immune state which is known to play a crucial role in the pathophysiology of septic shock and acute myocardial infarction.
About Nangibotide
Nangibotide is the formulation of the active ingredient LR12, which is a 12 amino-acid peptide prepared by chemical synthesis. LR12 is a specific TREM-1 inhibitor, acting as a decoy receptor and interfering in the binding of TREM-1 and its ligand. In preclinical septic shock models, nangibotide was able to restore appropriate inflammatory response, vascular function, and improved animals’ survival post septic shock.
About ESSENTIAL study:
The Efficacy and Safety Study Exploring Nangibotide Treatment in COVID-19 pAtients with ventiLatory support, is a randomized, double-blind, placebo-controlled confirmatory study with adaptive features that will be performed in Europe. This is a pivotal study and it is expected that based on its results, nangibotide could be registered in this indication. The first part of the study (i.e.: 60 patients) has been already finalized and assessed by an independent data monitoring committee with excellent safety results. The study will recruit up to 730 patients in up to 40 sites. Several interim and futility analyses are foreseen as part of the adaptive design of the study.
About Bpifrance
Bpifrance is the French national investment bank: it finances businesses – at every stage of their development – through loans, guarantees, equity investments and export insurances. Bpifrance also provides extra-financial services (training, consultancy.). to help entrepreneurs meet their challenges (innovation, export…).
For more information, please visit: www.bpifrance.fr and presse.bpifrance.fr
Follow us on Twitter: @Bpifrance - @BpifrancePresse
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210712005071/en/
Contact information
Media
Inotrem
Anne REIN - Strategies & Image (S&I)
anne.rein@strategiesimage.com
+33 6 03 35 92 05
Bpifrance
Sophie Santandrea
Sophie.santandrea@bpifrance.fr
+33 1 45 65 51 62
Secrétariat général pour l’investissement
presse.sgpi@pm.gouv.fr
+ 33 1 42 75 64 58
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Man & Science Completes Implantation in ONFIELD First-in-Human Study of Miniaturised ONS System for Chronic Cluster Headache19.11.2026 09:00:00 EET | Press release
Man & Science, a Belgian-based medical device company specialised in miniaturised neurostimulation technologies, today announced that all ten patients have been implanted and activated in its ONFIELD first-in-human pilot study of a miniaturised occipital nerve stimulation (ONS) implant for cluster headache, and that early clinical responses are encouraging. The ONFIELD study is evaluating the safety and feasibility of the Man & Science implant in patients whose cluster headaches remain inadequately controlled despite available treatments. All ten patients planned for this stage of the study have now received the implant and are being followed by the participating clinical team. Early observations show reductions in attack frequency in the patients assessed to date. No serious adverse events related to the implant surgery or the device have been reported so far. A severe and difficult-to-treat neurological disorder Cluster headache is a severe neurological disorder characterised by recu
Ant International Launches Whale Orchestration Protocol Under MAS’ BLOOM Initiative to Connect Tokenised Money Market Funds and Tokenised Deposits19.11.2026 08:00:00 EET | Press release
Ant International today announced the launch of the Whale Orchestration Protocol, a major upgrade to its blockchain-based wholesale settlement platform, WhaleRTP. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118947513/en/ Developed under the Monetary Authority of Singapore’s (MAS) BLOOM1 (Borderless, Liquid, Open, Online, Multi-currency) initiative, the protocol enables seamless Delivery-versus-Payment (DvP) transactions between tokenised deposits and tokenised money market funds. Through WhaleRTP, the Whale Orchestration Protocol enables secure and atomic settlement between tokenised deposits and tokenised money market funds, overcoming traditional fund settlement delays. This unlocks immediate liquidity for the company's real-time global treasury management, allowing idle capital to be deployed in real time. Ant International has already completed pilot transactions in partnership with DBS and Franklin Templeton, who
RSA Compliance Advisor Closes the Governance Gaps Between Audits19.11.2026 08:00:00 EET | Press release
RSA, the identity standard for government agencies, finance, and high-assurance organizations, today announced the general availability of RSA Compliance Advisor, a new capability within RSA® Governance & Lifecycle, the RSA identity governance and administration (IGA) solution, that maps identity governance controls directly to regulatory requirements and reports on compliance posture continuously. Governments and regulators keep raising the bar. GDPR, CJIS, HIPAA, NIST, and POPIA each carry hundreds of requirements, and new regulatory activity keeps adding more. Despite growing regulatory requirements, most compliance programs still confirm their posture the way they did a decade ago: quarterly reviews, annual certifications, manually built spreadsheets. This reactive, periodic assessment doesn’t account for access that changes every day in between. A program built on point-in-time checkpoints can look compliant on the day of the audit and still carry risk that never gets seen. RSA Co
NETS and Ant International Deepen Partnership to Empower Singapore’s Businesses for a Future in Agentic Commerce with Agentic Mobile Protocol19.11.2026 07:30:00 EET | Press release
Network for Electronic Transfers (NETS), Singapore’s leading payment services group, and Ant International are deepening their partnership to help businesses across Singapore reach new customers, simplify their operations and thrive in the era of agentic commerce by building a more connected mobile ecosystem well adapted to the AI era. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118997808/en/ Lawrence Chan, Group CEO, NETS (L) and Peng Yang, CEO, Ant International (R) NETS and Ant International signed a Memorandum of Understanding (MOU) at the Singapore Fintech Festival 2026 to explore a collaboration that draws on NETS’ digital payments services and Ant International’s Agentic Mobile Protocol (AMP) as well as its full stack of AI-native solutions. The expanded partnership spans several areas of strategic cooperation: Bringing agentic commerce capabilities to businesses of all sizes across Singapore NETS will become th
SBC Medical Group Reports Cybersecurity Incidents in Japan19.11.2026 06:39:00 EET | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) ("SBC Medical Group" or the "Company"), a provider of comprehensive management services to medical corporations and their clinics, today reported the occurrence of recent cybersecurity incidents involving customer information associated with certain clinics in Japan, along with the status of its response. Overview of the Incidents On November 16, 2026, unauthorized access occurred to certain databases within a website system managed and operated by SBC Medical Group, Ltd., the Company’s, Japanese subsidiary, in connection with its management services in Japan. The Company confirmed that an unauthorized third party accessed and extracted customer information. The method of intrusion and full scope remain under investigation. Based on current information, the information obtained and the number of affected customers are as follows: Category Types of information Individuals Period Basic personal information (without reservation or trea
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
